SYRS
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY-1425 and SY-1365.
Syros Pharmaceuticals, Inc. (SYRS) is rated D+ (1.7/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D-). The rating has held at D+ for 13 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2023-12-31 | C+ (2.5) | C+ (2.5) | D- (1.0) | D (1.2) | D (1.5) | D+ (1.7) |
| 2023-09-30 | C+ (2.5) | C- (2.0) | D- (1.0) | D (1.2) | D (1.5) | D+ (1.6) |
| 2023-06-30 | C+ (2.5) | F (0.5) | D+ (1.8) | D (1.2) | D (1.5) | D (1.5) |
| 2023-03-31 | C+ (2.5) | F (0.5) | D+ (1.8) | D (1.2) | D (1.5) | D (1.5) |
| 2022-09-30 | C+ (2.5) | D- (0.8) | D+ (1.8) | D (1.2) | D (1.5) | D+ (1.6) |